Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin
about
No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coliExploiting adaptive laboratory evolution of Streptomyces clavuligerus for antibiotic discovery and overproductionMaintaining fluoroquinolone class efficacy: review of influencing factors.BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei.Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusThe magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureusFluoroquinolone-resistant uncomplicated urinary tract infections, Chinese herbal medicine may provide help.Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus.Bifunctional antimicrobial conjugates and hybrid antimicrobials.Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes.Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients.
P2860
Q24627750-FD34F8F1-60C2-4E62-8A75-3F933BBF764AQ28481642-4ABAB011-F5D3-4BD5-9BDF-9285CC38C1C7Q30310427-E9BEBE8A-EC1E-42D2-A483-480C65DB70FDQ33200347-E3AD7955-BBAA-4BE1-9AF3-993501F0144CQ33555316-5C8257E3-B4C3-4671-8B77-CA379F30A86CQ33836597-512337D6-D6CC-4BA8-95E4-8EEBDDEE9CC8Q34141233-0BF69862-E79B-43BE-9339-7DACE9518327Q34478074-C4A83CF0-2D7E-4956-AD82-56A7CD7FD54AQ34680578-740D1267-00FF-44E2-9FA6-4877B5C138A0Q35657071-64DE110A-4F25-4304-92F9-2D695D176043Q35873418-D77FFAE0-AEF1-4962-9788-4F90D3452D46Q37624733-381C6ED5-7EE7-499C-A302-B67A21D285DFQ40098505-24CB49FF-0A84-41D6-ADAD-0D95C30F0869Q40203926-CDB3F4CB-686D-4B2F-B9B7-26C1176FED9DQ44904811-2C69A166-F60A-4E1A-92E3-2C85ABD2CC3EQ44912219-E3A2A9CD-E250-4B61-BAAC-B2C218CB6570Q46557679-230B5FB7-A27A-45DD-A7C8-33B6EFF585EAQ51547630-506BAC80-CBCD-430D-A144-91BCFD61DBEFQ54446069-AA518B57-DFD6-46DB-88C0-92F040C69537
P2860
Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@ast
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@en
type
label
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@ast
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@en
prefLabel
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@ast
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@en
P2093
P2860
P1476
Phenotypic resistance of Staph ...... evofloxacin, and trovafloxacin
@en
P2093
Dworkin RJ
Gilbert DN
Grunkemeier G
Kohlhepp SJ
Leggett JE
Slaughter SE
P2860
P304
P356
10.1128/AAC.45.3.883-892.2001
P407
P577
2001-03-01T00:00:00Z